EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Targeting c‐Myc enhances immunotherapy efficacy in combination with Ras inhibitor in triple‐negative breast cancer

Xiaojie Liang iD, Yiqiu Liu, Ye Zhu, Yuhan Zhao, Fan Ye, Fangyan Gao, Yaqin Shi, Xiaoxiang Guan

Clinical and Translational Medicine · 2025-10 · 15 (10)

DOI: 10.1002/ctm2.70484 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical and Translational Medicine, online erschienen am 29.09.2025. Verfasst von Xiaojie Liang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, Immunotherapy, Proto-Oncogene Proteins c-myc, ras Proteins. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Triple‐negative breast cancer (TNBC), which lacks hormone receptors and HER2 expression, presents substantial therapeutic challenges in breast cancer treatment. The efficacy of immunotherapy frequently suffers from the immunosuppressive nature of tumour microenvironment (TME). Hence, discovering effective targets to hinder TNBC progression and bolster immunotherapy's effectiveness is paramount. Previous research from our team indicated notable upregulation of c‐Myc in TNBC, and suppressing c‐Myc enhances the efficacy of PD‐L1 blockade in murine models; nevertheless, the precise mechanisms underlying this phenomenon remain elusive.

Methods

We analysed c‐Myc expression and implemented a systematic drug library screening strategy alongside c‐Myc knockdown to pinpoint potential synergistic agents in TNBC cells. To decipher the regulatory mechanisms of this synergy on cellular malignancy, we conducted cell cycle analysis, cell interaction assays, and RNA‐sequencing. Additionally, we established orthotopic and lung metastasis murine models assess how combination therapy influences PD‐L1 blockade efficacy.

Results

Elevated c‐Myc was observed in TNBC and the Ras inhibitor Salirasib was identified as a potent synergistic agent from cell cycle drug library in c‐Myc‐overexpressing TNBC. The application of Salirasib combined with c‐Myc knockdown markedly suppressed tumour cell aggressiveness and induced apoptosis in vitro. Mechanistically, RNA sequencing revealed that the combination therapy blocked MCM2‐mediated DNA replication in TNBC cells, causing G1/S phase arrest and enhancing tumour suppression. In vivo, the combination significantly improved PD‐L1 blockade efficacy, leading to reduction of tumour volume, inhibition of lung metastases, and remodelling of the immune microenvironment in murine TNBC models.

Conclusions

In summary, our investigation identifies a molecular vulnerability in c‐Myc‐driven TNBC, where Ras inhibition reinforces c‐Myc‐targeted therapy and potentiates immune checkpoint blockade, presenting a promising strategy to improve immunotherapy efficacy in TNBC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Triple Negative Breast NeoplasmsImmunotherapyProto-Oncogene Proteins c-mycras ProteinsAnimalsHumansMiceFemaleCell Line, TumorTumor MicroenvironmentB7-H1 Antigen

Stichwörter der Autor:innen

Minichromosome Maintenance Complex Component 2 (MCM2)Salirasibc‐Mycimmunotherapytriple‐negative breast cancer (TNBC)tumour microenvironment (TME)

Substanzen

Proto-Oncogene Proteins c-mycMYC protein, humanras ProteinsB7-H1 Antigen

Autor:innen und Institutionen

  • Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China.
  • Department of Oncology, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China.
  • Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing Medical University, Nanjing, Jiangsu, China.

ORCID-Profile: Xiaojie Liang

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Liang, X., Liu, Y., Zhu, Y., Zhao, Y., Ye, F., Gao, F., Shi, Y., & Guan, X. (2025). Targeting c‐Myc enhances immunotherapy efficacy in combination with Ras inhibitor in triple‐negative breast cancer. Clinical and Translational Medicine, 15(10). https://doi.org/10.1002/ctm2.70484

Vancouver

Liang X, Liu Y, Zhu Y, Zhao Y, Ye F, Gao F, et al. Targeting c‐Myc enhances immunotherapy efficacy in combination with Ras inhibitor in triple‐negative breast cancer. Clinical and Translational Medicine. 2025;15(10). doi:10.1002/ctm2.70484

BibTeX
@article{Liang2025,
  author = {Liang, Xiaojie and Liu, Yiqiu and Zhu, Ye and Zhao, Yuhan and Ye, Fan and Gao, Fangyan and Shi, Yaqin and Guan, Xiaoxiang},
  title = {Targeting c‐Myc enhances immunotherapy efficacy in combination with Ras inhibitor in triple‐negative breast cancer},
  journal = {Clinical and Translational Medicine},
  year = {2025},
  volume = {15},
  number = {10},
  doi = {10.1002/ctm2.70484}
}
Kostenlos starten →